Corvus Pharmaceuticals (CRVS) Capital Expenditures (2015 - 2026)
Corvus Pharmaceuticals (CRVS) posted quarterly Capital Expenditures of $91000.0 for Q1 2026, up 152.78% year-over-year from $36000.0 in Q1 2025, and up 118.69% quarter-over-quarter from -$487000.0 in Q4 2025.
Corvus Pharmaceuticals (CRVS) Capital Expenditures (2015 - 2026) Analysis & Trends
Corvus Pharmaceuticals' Capital Expenditures history runs 12 years deep, the most recent figure standing at $91000.0 for Q1 2026.
- In Q1 2026, Capital Expenditures rose 152.78% year-over-year to $91000.0; the TTM figure through Mar 2026 stood at -$283000.0 (down 181.32% YoY), while the FY2025 annual figure was -$338000.0, down 1307.14% from the prior year.
- Capital Expenditures for Q1 2026 stood at $91000.0, up from -$487000.0 in the prior quarter.
- The five-year high for Capital Expenditures was $893000.0 in Q4 2024, with the low at -$487000.0 in Q4 2025.
- The 5-year median for Capital Expenditures is $21000.0 (2022), against an average of $6666.7.
- The sharpest annual moves came in 2024 and 2025: Capital Expenditures slumped 935.29% in 2024, then surged 206.8% in 2025.
- Corvus Pharmaceuticals' Capital Expenditures stood at $257000.0 in 2022, then slumped by 86.77% to $34000.0 in 2023, then surged by 2526.47% to $893000.0 in 2024, then plunged by 154.54% to -$487000.0 in 2025, then surged by 118.69% to $91000.0 in 2026.
- Business Quant data shows CRVS's Capital Expenditures at $91000.0 in Q1 2026, -$487000.0 in Q4 2025, and $314000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capital Expenditures (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 112.20 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 240.20 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 2.29 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 25.02 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 572,662.23 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 251.02 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 34.68 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 6.26 Mn |
| 10 | Corvus Pharmaceuticals | 1.25 Bn | 1.04 Bn | - | 582,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 582,000.00 |
| Jun 30, 2026 | 582,000.00 |
| Mar 31, 2026 | 91,000.00 |
| Mar 31, 2026 | 91,000.00 |
| Dec 31, 2025 | -487,000.00 |
| Dec 31, 2025 | -487,000.00 |
| Sep 30, 2025 | 314,000.00 |
| Sep 30, 2025 | 314,000.00 |
| Jun 30, 2025 | -201,000.00 |
| Jun 30, 2025 | -201,000.00 |
| Mar 31, 2025 | 36,000.00 |
| Mar 31, 2025 | 36,000.00 |
| Dec 31, 2024 | 893,000.00 |
| Dec 31, 2024 | 893,000.00 |
| Sep 30, 2024 | -294,000.00 |
| Sep 30, 2024 | -294,000.00 |
| Jun 30, 2024 | -287,000.00 |
| Jun 30, 2024 | -287,000.00 |
| Mar 31, 2024 | -284,000.00 |
| Mar 31, 2024 | -284,000.00 |